Logo image
Investigation of epstein-barr virus as a potential cause of B-cell non-Hodgkin lymphoma in a prospective cohort
Journal article   Open access   Peer reviewed

Investigation of epstein-barr virus as a potential cause of B-cell non-Hodgkin lymphoma in a prospective cohort

Anneclaire J De Roos, Otoniel Martínez-Maza, Keith R Jerome, Dana K Mirick, Kenneth J Kopecky, Margaret M Madeleine, Larry Magpantay, Kerstin L Edlefsen and Andrea Z Lacroix
Cancer epidemiology, biomarkers & prevention, v 22(10), pp 1747-1755
Oct 2013
PMID: 23885038
url
https://doi.org/10.1158/1055-9965.epi-13-0240View
Published, Version of Record (VoR)Maybe Open Access (Publisher Bronze) Open

Abstract

Aged Case-Control Studies Cohort Studies Epstein-Barr Virus Infections - epidemiology Epstein-Barr Virus Infections - virology Female Humans Lymphoma, Non-Hodgkin - epidemiology Lymphoma, Non-Hodgkin - virology Middle Aged Postmenopause Prospective Studies
We hypothesized that poor control of Epstein-Barr virus (EBV) infection, leading to reactivation of the virus, increases the risk of non-Hodgkin lymphoma (NHL) in the general population of primarily immunocompetent persons. We conducted a case-control study nested within the Women's Health Initiative Observational Study cohort in which we measured antibodies to EBV antigens [immunoglobulin G (IgG) to viral capsid antigen (VCA), nuclear antigen (EBNA1), and early antigen-diffuse (EA-D)] and EBV DNA load in prediagnostic samples of 491 B-cell NHL cases and 491 controls. We found no association with established EBV infection, based on seropositivity for VCA. Seropositivity for EBNA1 was associated with decreased risk of B-cell NHL, overall [OR = 0.5; 95% confidence interval (CI), 0.3-0.8] and for each of the histologic subtypes examined. Increased risk of chronic lymphocytic leukemia (CLL) and related subtypes was observed with higher levels of EBV DNA and antibody to EA-D, both markers reflective of reactivation. These associations were strongest for cases with the shortest time interval between blood draw and diagnosis. In balance, these results do not provide strong evidence of EBV playing a causal role in B-cell NHL in general population women. The associations we observed may reflect increased risk of NHL with underlying immune impairment or could be due to reverse causation. Further characterization of the subtype-specific association with CLL is warranted. Exclusion of cases with preclinical disease markers (such as monoclonal B-lymphocytosis for CLL) may help rule out reverse causation in future studies.

Metrics

9 Record Views
17 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Oncology
Public, Environmental & Occupational Health
Logo image